Experiences of the Janus Serum Bank in Norway.

Jellum, Egil; Andersen, Aage; Lund‐Larsen, Per G.; Theodorsen, L.; Orjasaeter, H

doi:10.1289/ehp.95103s385

Cited by 62 publications

(37 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The serum bank contains samples from approximately 333 000 people (151 000 women) and 10% are blood donors. The sera have been stored at À251C (Jellum et al, 1993(Jellum et al, , 1995.…”

Section: Methodsmentioning

confidence: 99%

Breast cancer, cytomegalovirus and Epstein–Barr virus: a nested case–control study

et al. 2010

Self Cite

View full text Add to dashboard Cite

BACKGROUND: We investigated whether elevation in serum cytomegalovirus (CMV) or Epstein -Barr virus (EBV) immunoglobulin G (IgG) antibody levels precedes the development of breast cancer. METHODS: A nested case -control study was carried out within the Janus Serum Bank cohort. Two serum samples, one taken at least 4 years before diagnosis (sample 2) and an earlier sample (sample 1) from 399 women with invasive breast cancer and from 399 controls, matched for date of blood samples and age were tested for CMV and EBV IgG antibodies. Odds ratios (ORs) with 95% confidence intervals (CIs) for CMV and EBV seroconversion between the samples and unit changes in IgG optical density (OD) examined as a continuous variable were calculated using conditional logistic regression. RESULTS: Eleven cases and three controls seroconverted for CMV IgG between the first and second blood samples, with an adjusted OR for CMV IgG seroconversion of 4.0 (95% CI ¼ 1.1 -14.4). The risk of breast cancer, adjusted for parity, increased per unit difference in CMV OD between samples (OR ¼ 1.7, 95% CI ¼ 1.1 -2.5). In an analysis restricted to parous cases and age-matched parous controls, the OR for CMV seroconversion for IgG between the two samples, adjusted for parity and age at first birth, was 9.7 (95% CI ¼ 1.2 -77.3). The EBV seroconversion or change in EBV OD was not associated with risk of breast cancer. CONCLUSION: Our hypothesis that elevation in serum CMV IgG antibody levels precedes the development of breast cancer in some women is supported by the results of this study. Changes in EBV IgG antibody are not associated with risk of breast cancer.

show abstract

“…The serum bank contains samples from approximately 333 000 people (151 000 women) and 10% are blood donors. The sera have been stored at À251C (Jellum et al, 1993(Jellum et al, , 1995.…”

Section: Methodsmentioning

confidence: 99%

Breast cancer, cytomegalovirus and Epstein–Barr virus: a nested case–control study

et al. 2010

Self Cite

View full text Add to dashboard Cite

show abstract

“…25 The samples have been collected from men who participated in county health examinations, mostly for cardiovascular diseases and from blood donors. The participants in the health examinations were recruited from several counties in Norway.…”

Section: Cohortsmentioning

confidence: 99%

Circulating enterolactone and prostate cancer risk: A Nordic nested case‐control study

Stattin

Adlercreutz

Tenkanen³

et al. 2002

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Whereas phase I enrolled subjects of a wide age range, phase II primarily focused on 40-to 42-year-old subjects. The response rate to the population-based invitation to participate was 85% in phase I and 75% in phase II (Jellum et al, 1995).…”

Section: Subjectsmentioning

confidence: 99%

A prospective study of the relationship between prediagnostic Human Papillomavirus seropositivity and HPV DNA in subsequent cervical carcinomas

et al. 2002

Self Cite

View full text Add to dashboard Cite

Several prospective studies with invasive carcinoma as endpoint have supported Human Papillomavirus as a cause of cervical carcinoma. However, the largest study used seroepidemiology and did not analyse presence of Human Papillomavirus DNA in the subsequent tumour. Linkage of serum bank registries and cancer registries had identified 196 women with a registered cervical carcinoma after donation of a serum sample. For the present study, biopsies for 127 cases could be located, verified to contain invasive carcinoma and be amplified by PCR. Three control women who had remained alive and without cervical carcinoma during an equal length of follow-up had been matched to each of the case women and tested for HPV antibodies. Presence of Human Papillomavirus DNA in the tumours was analysed by general primer and type specific PCR. HPV16-seropositive women had a relative risk of 4.4 (95% CI: 2.2 -8.8) to develop cervical carcinoma carrying HPV16 DNA. By contrast, there was no excess risk for Human Papillomavirus 16-seropositive women to develop cervical carcinoma devoid of HPV16 DNA. Prediagnostic HPV16 seropositivity was strongly correlated with later HPV16 DNA positivity of the tumour (P50.001) and prediagnostic HPV18 seropositivity correlated with HPV18 DNA in the tumour (P50.03). The link between prediagnostic seropositivity and type of viral DNA in the cancer implies that the carcinogenic effect of infection with these viruses is dependent on persistent presence of type-specific viral DNA. The most important risk factor for development of cervical carcinoma is infection with the oncogenic types of human papillomavirus (HPV). A series of cross-sectional case-control studies, based both on HPV DNA testing of tumours (Walboomers et al, 1999), measurement of serum HPV antibodies (Dillner et al, 1995), or both (Nonnenmacher et al, 1995;de Sanjose et al, 1996) have found a consistent and strong association between HPV and cervical carcinoma.That the association between HPV and cervical carcinoma is causal is supported also by prospective studies, both with cervical intraepithelial neoplasia (Koutsky et al, 1992;Chua et al, 1996) and invasive cervical carcinoma as the end-point Shah et al, 1997;Vonka et al, 1999;Wallin et al, 1999). However, most prospective studies are based on limited numbers of cases. The largest study to date is a seroepidemiological study that contained 182 cases (Dillner et al, 1997). However, prediagnostic seropositivity and type of HPV DNA in subsequently occurring invasive carcinoma has not been previously performed. Combining seroepidemiological studies with HPV DNA analyses in prospective studies could be important for several reasons. For example, there are indications that prior or ongoing HPV infections may interact in a complex fashion in cervical carcinogenesis (Luostarinen et al, 1999;Silins et al, 1999). By comparing prediagnostic assessment of virus exposure with presence of virus DNA in the tumour, it could be possible to infer whether type-specific persistence of HPV is the predominant...

show abstract

Experiences of the Janus Serum Bank in Norway.

Cited by 62 publications

References 12 publications

Breast cancer, cytomegalovirus and Epstein–Barr virus: a nested case–control study

Breast cancer, cytomegalovirus and Epstein–Barr virus: a nested case–control study

Circulating enterolactone and prostate cancer risk: A Nordic nested case‐control study

A prospective study of the relationship between prediagnostic Human Papillomavirus seropositivity and HPV DNA in subsequent cervical carcinomas

Contact Info

Product

Resources

About